Europe Non-Alcoholic Steatopatitis Market Comprehensive Study, Industry research -2028

The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.

Non-Alcoholic Steatohepatitis (NASH) remains significantly under-recognized. Increasing awareness among both the general public and primary care physicians (PCPs) is crucial for establishing structured referral pathways and enabling early detection. Effective patient education campaigns and clear referral protocols can identify more individuals needing specialist evaluation, thereby expanding the patient pool for management and research.

To address this need, the NASH Education Program launched its inaugural public education campaign on June 12, 2018, designated as "International NASH Day." This initiative aimed to raise awareness of non-alcoholic fatty liver disease (NAFLD) and its advanced form, NASH, which affects over 115 million people globally.

Building on this momentum, the digital platform NASH 24X7 intensified efforts on International NASH Day 2019 (June 12). Their multi-pronged approach included Healthcare Professional (HCP) support, enhanced patient awareness initiatives, and press/TV releases. A key component of their patient education strategy involved the "NASH Crusaders" collaborating with HCPs across India to conduct numerous workshops, both large and small. These sessions focused on liver health and the critical role of a healthy lifestyle in preventing NAFLD/NASH progression.

Leveraging digital, print, and broadcast media, these campaigns executed significant outreach efforts on International NASH Day to engage the general public effectively through press releases and television programming.

Concurrently, the Europe non-alcoholic steatopatitis market is anticipated to experience substantial growth, projected at a good Compound Annual Growth Rate (CAGR) during the forecast period, reflecting the increasing focus on this condition.

Key Changes Made:

1. Conciseness: Removed redundancy (e.g., repeated phrases like "raise awareness").
2. Flow & Structure: Organized information chronologically and thematically (problem -> solution/campaigns -> specific actions -> market context).
3. Clarity: Simplified sentences and improved transitions. Defined acronyms clearly (HCP).
4. Word Count: Reduced significantly from the original while retaining all key points (115 million, International NASH Day dates, NASH Education Program, NASH 24X7 actions, India workshops, media use, Europe market projection).
5. Focus: Kept the emphasis on awareness efforts while briefly noting the market growth as a related point.
6. Terminology: Used consistent terminology (NASH, NAFLD, HCP).

The Europe non-alcoholic steatopatitis market is a significant segment within the broader liver disease treatment landscape, driven by the increasing prevalence of obesity and related metabolic disorders. Here's a breakdown of its segmentation and key players, based on the provided information:

Europe non-alcoholic steatopatitis market Segmentation:

Europe non-alcoholic steatopatitis market Product Type:

• Vitamin E and Pioglitazone
• Ocaliva (Obeticholic Acid)
• Elafibranor
• Selonsertib & Cenicriviroc (expected to be the fastest-growing segment)
• Others (including other investigational and approved therapies)

Europe non-alcoholic steatopatitis market Application:

• Treatment (dominated the market in 2020)
• Diagnosis

Europe non-alcoholic steatopatitis market Sales Channel:

• Hospital Pharmacy
• Online Provider
• Retail Pharmacy (dominated the market in 2020)

Europe non-alcoholic steatopatitis market Country:

• Germany (dominated the market in 2020)
• The UK
• France
• Italy
• Spain
• Rest of Europe

Leading Companies in the Europe non-alcoholic steatopatitis market:

• Cadila Pharmaceutical
• Intercept Pharmaceutical
• Novartis AG
• Galmed Pharmaceutical
• GENFIT
• ONE WAY LIVER SI
• BioPredictive S.A.S
• Siemens Healthineers AG
• Laboratory Corporation of America Holdings

Additional Insights from Search Results: Europe non-alcoholic steatopatitis market

Market Size & Growth:As per our report Europe Non-Alcoholic Steatopatitis Market, the market size is valued at US$ 496.83 Million in 2021, projecting it to reach US$ 6,765.21 Million by 2028. This translates to a CAGR of approximately 45.2% during the forecast period.

Key Drivers: The increasing prevalence of obesity globally is a major growth factor for the NASH treatment market.

Challenges: A major challenge is the lack of appropriate, FDA-approved treatments that can halt or reverse the progression of hepatic fibrosis, cirrhosis, and hepatocellular carcinoma.

Emerging Trends:

• Increased interest in non-invasive diagnostics.
• Development of novel therapies and pharmacological treatments targeting various metabolic, inflammatory, and fibrotic pathways.
• Shift towards combination therapies due to the complex pathogenesis of NASH.
• Rising adoption of telemedicine and e-commerce platforms for healthcare products, driving the online providers segment.

Specific Company Activities:

• Intercept Pharmaceuticals: Their lead product is Ocaliva (obeticholic acid, OCA), though its marketing authorization in Europe was revoked in August 2024. They were acquired by Alfasigma S.p.A.
• Novartis AG: Has a development portfolio in non-viral liver diseases, including NASH, and has entered clinical collaborations to evaluate combination therapies.
• Galmed Pharmaceuticals: Focused on developing Aramchol, with recent patent grants for combination therapy with Resmetirom. They are also exploring broader cardiometabolic indications.
• GENFIT: Has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and a rapidly expanding R&D portfolio in liver diseases. Their product elafibranor (Iqirvo®) has recently received pricing and reimbursement approval in Italy.
• ONE WAY LIVER S.L.: A biotechnology company offering diagnostic products and metabolomics services for liver diseases, including OWLiver for steatosis and NASH diagnosis.
• BioPredictive S.A.S: Offers non-invasive diagnostic tests for liver diseases, including NASH-FibroTest, SteatoTest, and NashTest.
• Siemens Healthineers AG & Laboratory Corporation of America Holdings (Labcorp): These companies are involved in broader healthcare diagnostics and services, which would include solutions and testing relevant to NASH diagnosis and monitoring.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

Author’s Bio:

Suryakant Gadekar

Senior Market Research Expert at Business Market Insights